Sunshine Biopharma Inc. is a pharmaceutical company. It focused on the research, development and commercialization of oncology and antiviral drugs. Sunshine Biopharma Inc. is based in MONTREAL.
| Revenue (Most Recent Fiscal Year) | $36.31M |
| Net Income (Most Recent Fiscal Year) | $-5.97M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 0.12 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.10 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -15.73% |
| Net Margin (Trailing 12 Months) | -17.94% |
| Return on Equity (Trailing 12 Months) | -26.36% |
| Return on Assets (Trailing 12 Months) | -20.60% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.46 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.30 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 1.87 |
| Book Value per Share (Most Recent Fiscal Quarter) | $7.10 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.15 |
| Earnings per Share (Most Recent Fiscal Year) | $-14.40 |
| Diluted Earnings per Share (Trailing 12 Months) | $-10.15 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Common Shares Outstanding | 3.88M |
| Free Float | 3.86M |
| Market Capitalization | $4.38M |
| Average Volume (Last 20 Days) | 1.27M |
| Beta (Past 60 Months) | 1.17 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.48% |
| Percentage Held By Institutions (Latest 13F Reports) | 41.98% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |